34803-66-2

Basic information

• Product Name: 1-(2-Pyridyl)piperazine
• Synonyms: 2-pyridyl piperazine;1-(2-PYRIDYL)PIPERAZINE, 99.5+%;2-(1-piperazino)pyridine;2-piperazinopyridine;1-(Pyridin-2-yl)piperazine 98%;N-(4-PYRIDYL) PIPERAZINE;1-PYRIDIN-2-YL-PIPERAZINE >98%;1-(2-Pyridyl)piperazine ,98%
• CAS NO: 34803-66-2
• Molecular Formula: C₉H₁₃N₃
• Molecular Weight: 163.22
• EINECS: 252-220-3
• Product Categories: Piperidines, Piperidones, Piperazines;pharmacetical;API intermediates;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 34803-66-2.mol

Chemical Properties

• Melting Point: 92-94
• Boiling Point: 120-122 °C2 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: Clear colorless to yellow/Liquid
• Density: 1.072 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.000467mmHg at 25°C
• Refractive Index: n20/D 1.595(lit.)
• Storage Temp.: Flammables area
• Solubility: Soluble in Chloroform, Methanol.
• PKA: 8.63±0.10(Predicted)
• Water Solubility: >500 g/L (20 ºC)
• Sensitive: Air Sensitive
• BRN: 140423
• CAS DataBase Reference: 1-(2-Pyridyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Pyridyl)piperazine(34803-66-2)
• EPA Substance Registry System: 1-(2-Pyridyl)piperazine(34803-66-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: 2735
• WGK Germany: 3
• F: 10-34
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 34803-66-2(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Applications:
1-(2-Pyridyl)piperazine is used as a selective α2-adrenoceptor antagonist for its sympatholytic activity, which can be beneficial in the development of medications targeting various physiological conditions.
2. Used in Environmental Monitoring:
1-(2-Pyridyl)piperazine is used as a reagent for determining the presence of aliphatic and aromatic isocyanates in air, which is crucial for assessing and maintaining air quality and safety.
3. Used in Metabolite Research:
1-(2-Pyridyl)piperazine, being a metabolite of Azaperone (A802200), can be utilized in research related to the metabolism and pharmacokinetics of this compound, potentially aiding in the development of new drugs or understanding the effects of existing ones.

InChI:InChI=1/C9H13N3/c1-2-4-11-9(3-1)12-7-5-10-6-8-12/h1-4,10H,5-8H2/p+2

Upstream product

• 110-85-0 piperazine 
• 109-04-6 2-bromo-pyridine 
• 158399-58-7 ethyl-4-(2-pyridyl)-1-piperazine carboxylate 
• 109-09-1 2-chloropyridine 
• 77278-62-7 tert-butyl 4-(pyridin-2-yl)piperazine-1-carboxylate 
• 504-29-0 2-aminopyridine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 40004-68-0 2-<4-(pyridin-2-yl)piperazin-1-yl>ethanol 
• 102559-55-7 1,1-diphenyl-2-(4-pyridin-2-yl-piperazin-1-yl)-ethanol 
• 113091-12-6 1-[2-(N-ethyl-anilino)-ethyl]-4-[2]pyridyl-piperazine 
• 145208-85-1 1-methyl-4-(pyridin-2-yl)piperazine 
• 330865-56-0 N-phenyl-4-(pyridin-2-yl)piperazine-1-carbothioamide 
• 335282-70-7 4-[2]pyridyl-piperazine-1-carboxylic acid p-toluidide 
• 115036-73-2 1-(4-phenyl-piperazino)-2-(4-[2]pyridyl-piperazino)-ethane 
• 74130-01-1 1-Benzenesulfinyl-4-pyridin-2-yl-piperazine 
• 86523-85-5 β-[4-(pyridin-2-yl)-piperazino]-propionanilide 
• 63633-89-6 1-phenylsulfanyl-4-pyridin-2-yl-piperazine 
• 86523-75-3 N-(4-Nitro-phenyl)-3-(4-pyridin-2-yl-piperazin-1-yl)-propionamide 
• 86523-86-6 3-(4-Pyridin-2-yl-piperazin-1-yl)-N-o-tolyl-propionamide 
• 104374-07-4 N-(4-Hydroxy-phenyl)-3-(4-pyridin-2-yl-piperazin-1-yl)-propionamide 

Relevant articles and documents

Substituted indole compound and method and use thereof

The invention provides a new indole compound, pharmaceutically acceptable salts and medicinal preparations thereof, and a use of the new indole compound in selective inhibition of 5-hydroxytryptamine reuptake and /or excitation of a 5-HT1A receptor. The invention also relates to medicinal compositions comprising the compounds, and a method for treating the central nervous system dysfunction of mammals, especially humans by using the medicinal compositions.

Pd-Catalyzed Synthesis of Piperazine Scaffolds under Aerobic and Solvent-Free Conditions

A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiperazines under aerobic conditions is reported. Electron donating and sterically hindered aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an ecofriendly, cost-effective synthesis of these privileged structures.

Chrysin-piperazine conjugates as antioxidant and anticancer agents

Synthesis of 7-(4-bromobutoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one intermediate treating chrysin with 1,4-dibromobutane facilitated combination of chrysin with a wide range of piperazine moieties which were equipped via reacting the corresponding amines with bis(2-chloroethyl)amine hydrochloride in diethylene glycol monomethyl ether solvent. Free radical scavenging potential of prepared products was analyzed in vitro adopting DPPH and ABTS bioassay in addition to the evaluation of in vitro anticancer efficacies against cervical cancer cell lines (HeLa and CaSki) and an ovarian cancer cell line SK-OV-3 using SRB assay. Bearable toxicity of 7a-w was examined employing Madin-Darby canine kidney (MDCK) cell line. In addition, cytotoxic nature of the presented compounds was inspected utilizing Human bone marrow derived mesenchymal stem cells (hBM-MSCs). Overall, 7a-w indicated remarkable antioxidant power in scavenging DPPH+ and ABTS++, particularly analogs 7f, 7j, 7k, 7l, 7n, 7q, 7v, 7w have shown promising free radical scavenging activity. Analogs 7j and 7o are identified to be highly active candidates against HeLa and CaSki cell lines, whereas 7h and 7l along with 7j proved to be very sensitive towards ovarian cancer cell line SKOV-3. None of the newly prepared scaffolds showed cytotoxic nature toward hBM-MSCs cells. From the structure-activity point of view, nature and position of the electron withdrawing and electron donating functional groups on the piperazine core may contribute to the anticipated antioxidant and anticancer action. Different spectroscopic techniques (FT-IR, 1H NMR, 13C NMR, Mass) and elemental analysis (CHN) were utilized to confirm the desired structure of final compounds.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Discovery of a novel 5-HT3 antagonist/5-HT1A agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl} quinazolin-4(3 H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome

We have prepared a series of quinazolinone derivatives linked with piperazinylquinoline for the treatment of irritable bowel syndrome (IBS). Using pharmacophore analysis, we designed and synthesized compounds which bind to both serotonin receptor subtype 1A (5-HT1A) and subtype 3 (5-HT 3). Quinazolinone derivatives with a sulfur atom in the linker showed high affinity in in vitro assays, but low in vivo activity. Focusing on the linker to improve the pharmacokinetic profile, the sulfur atom in the linker was replaced with a methylene group. Further optimization led to the discovery of compound 17m (TZB-30878) (J. Pharmacol. Exp. Ther. 2007, 322, 1315 -1323, Patent WO2005082887 (A1), 2005), a novel 5-HT1A agonist/5-HT3 antagonist in the 3-aminoquinazolinone series. In in vivo functional assays, 17m dose dependently inhibited the Bezold-Jarisch reflex and induced 5-HT 1A-mediated behaviors, and in an IBS animal model, 17m significantly inhibited stress-induced defecation. Pretreatment by WAY-100635 (5-HT 1A antagonist) significantly attenuated but did not abolish the inhibitory effects of 17m. These results suggested that 17m exerted inhibitory effects via both 5-HT1A agonistic and 5-HT3 antagonistic activities and that 17m would be useful as a therapeutic agent for IBS.

TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

A triazole derivative of formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.

ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS

The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors, hi particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.

Discovery and Initial SAR of Arylsulfonylpiperazine Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)

High-throughput screening of a small-molecule compound library resulted in the identification of a series of arylsulfonylpiperazines that are potent and selective inhibitors of human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). Optimization of the initial lead resulted in the discovery of compound (R)-45 (11β-HSD1 IC50 = 3 nM).

FACTOR XA COMPOUNDS

The present invention is directed to novel compounds of Formula (I) and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.

Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same

Oligomeric compounds comprising a plurality of aminodiol monomer subunits joined by linking groups are provided, as well as libraries of such compounds and processes for preparing the oligomeric compounds and libraries.